David DeRemer

David DeRemer, Pharm.D., BCOP, FCCP, FHOPA

Clinical Associate Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 294-8891
Business Email: dderemer@cop.ufl.edu

About David DeRemer

David DeRemer received his B.S. Biology and Pharm.D. degrees from the University of Kentucky. Following graduation, he completed a Pharmacy Practice Residency and an Oncology specialty residency at the University of Kentucky Chandler Medical Center. He followed that with an Oncology Postdoctoral Fellowship focusing on Drug Discovery/Development at the University of Kentucky. DeRemer is a fellow of the American College of Clinical Pharmacy (ACCP) and the Hematology Oncology Pharmacist Association (HOPA). He is currently the President-Elect for HOPA and actively participates in multiple HOPA committees. He joined the University of Florida College of Pharmacy in September 2017 and is actively participating in early phase UF Health Cancer Center clinical trials.

Accomplishments

Fellow
Current · Hematology Oncology Pharmacist Association
Member
2017-Current · American Society of Clinical Oncology
Fellow
2015 · American College of Clinical Pharmacy
Best Paper
2014 · American College of Clinical Pharmacy
Practitioner of the Year
2012 · Georgia Society of Health-System Pharmacists
Member
2006-Current · Hematology/Oncology Pharmacy Association
Associate Member
2002-Current · American College of Clinical Pharmacy

Board Certifications

  • BCOP
    BPS

Research Profile

Research Interests: Early phase oncology clinical trials, pharmacogenomics in cancer, biomarkers, B-cell malignancies and supportive care in cancer

Publications

2021
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review.
Expert review of pharmacoeconomics & outcomes research. 1-19 [DOI] 10.1080/14737167.2021.1913056. [PMID] 33934691.
2021
Immunotherapy Management in Special Cancer Patient Populations.
JCO oncology practice. 17(5):240-245 [DOI] 10.1200/OP.20.00996. [PMID] 33710933.
2021
Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center.
Cardio-oncology (London, England). 7(1) [DOI] 10.1186/s40959-021-00097-9. [PMID] 33736707.
2020
How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Clinical pharmacology and therapeutics. 108(3):557-565 [DOI] 10.1002/cpt.1912. [PMID] 32460360.
2020
Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(3):647-654 [DOI] 10.1177/1078155219868758. [PMID] 31474214.
2018
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 24(10):2065-2071 [DOI] 10.1016/j.bbmt.2018.06.005. [PMID] 29906570.
2017
Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
Journal of pharmacy practice. 30(4):400-405 [DOI] 10.1177/0897190016659210. [PMID] 27432462.
2016
Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.
Pharmacotherapy. 36(2):218-29 [DOI] 10.1002/phar.1703. [PMID] 26890915.
2016
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 22(3):416-22 [DOI] 10.1177/1078155215585190. [PMID] 25956421.
2016
Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia.
The Journal of community and supportive oncology. 14(2):66-71 [DOI] 10.12788/jcso.0231. [PMID] 26955659.
2015
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 21(6):425-32 [DOI] 10.1177/1078155214541571. [PMID] 24986792.
2014
Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.
Oncotarget. 5(3):775-87 [PMID] 24519956.
View on: PubMed
2013
Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 70(7):589-97 [DOI] 10.2146/ajhp110608. [PMID] 23515511.
2013
Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Bone marrow transplantation. 48(10):1279-84 [DOI] 10.1038/bmt.2013.52. [PMID] 23584435.
2013
Romiplostim resistance in secondary failure of platelet recovery.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 19(4):369-72 [DOI] 10.1177/1078155212469640. [PMID] 23292974.
2012
Antiangiogenic therapy for cancer: an update.
Pharmacotherapy. 32(12):1095-111 [DOI] 10.1002/phar.1147. [PMID] 23208836.
2012
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(7):1128-35 [DOI] 10.1016/j.bbmt.2012.01.005. [PMID] 22248715.
2011
Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence.
Clinical science (London, England : 1979). 120(8):307-19 [PMID] 21488224.
View on: PubMed
2011
Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.
Cancer management and research. 3:65-78 [DOI] 10.2147/CMR.S11948. [PMID] 21556318.
2010
Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
Acta haematologica. 124(4):206-13 [DOI] 10.1159/000321504. [PMID] 21071929.
2009
Investigational drugs targeting FLT3 for leukemia.
Expert opinion on investigational drugs. 18(10):1445-56 [DOI] 10.1517/13543780903179278. [PMID] 19671038.
2008
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Clinical therapeutics. 30(11):1956-75 [DOI] 10.1016/j.clinthera.2008.11.014. [PMID] 19108785.

Education

Oncology Postdoctoral Fellowship
2004-2005 · University of Kentucky Chandler Medical Center
Hematology-Oncology Residency
2003-2004 · University of Kentucky Chandler Medical Center
Pharmacy Practice Residency
2002-2003 · University of Kentucky Chandler Medical Center
Pharm.D.
2002 · University of Kentucky
B.S.
1996 · University of Kentucky

Teaching Profile

Courses Taught
2018-2020
PHA5782C Patient Care 2
2020-2021
PHA5933 Select Top Pharmacy
2018-2021
PHA5876C Pt Care 8 Complex Pts
2019-2020
PHA6136 Clinical Applications of Precision Medicine: Oncology
2018-2019,2021
PHA5787C Pt Care 5: Endo
2018-2019,2021
PHA5784C Pt Care 4: GI and Renal
2018
PHA5878C Pt Care 3: Cv and Pulm
2021
PHA5787 Pharmacotherapy 5

Contact Details

Phones:
Business:
(352) 294-8891
Emails: